

DAFTAR PUSTAKA

1. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020/03/13. 2020 Apr;87(4):281–6.
2. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020/04/20. 2020 Jun;215:108427.
3. Krishnan A, Hamilton JP, Alqahtani SA, Woreta TA. COVID-19: An overview and a clinical update. World J Clin cases. 2021 Jan 6;9(1):8–23.
4. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls. 2021 Sep;
5. WHO. WHO Coronavirus (COVID-19) Dashboard With Vaccination Data [Internet]. [cited 2021 Dec 1]. Available from: <https://covid19.who.int/>
6. Propinsi Sumatera Barat. Sumbar Tanggap Corona [Internet]. [cited 2021 Dec 2]. Available from: <https://corona.sumbarprov.go.id/>
7. Chowdhury SD, Oommen AM. Epidemiology of COVID-19. J Dig Endosc. 2020 Mar;11(1):3.
8. Lee CY-P, Lin RTP, Renia L, Ng LFP. Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control. Front Immunol. 2020 Apr 24;11:879.
9. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr;323(13):1239–42.
10. PDPI, PERKI, PAPDI, PERDATIN, IDAI. Pedoman tatalaksana COVID-19 Edisi 3 Desember 2020. Pedoman Tatalaksana COVID-19. 2020. 36–37 p.
11. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. Br Infect Assoc. 2020;81:e16–25.
12. Naik RR, Shakya AK. Therapeutic Strategies in the Management of COVID-19. Front Mol Biosci. 2021 Feb 4;7:636738.
13. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020/05/13. 2020 Aug;288(2):192–206.
14. Kichloo A, Albosta M, Kumar A, Aljadah M, Mohamed M, El-Amir Z, et al. Emerging therapeutics in the management of COVID-19. World J Virol. 2021 Jan 25;10(1):1–29.

15. Chalmers JD, Crichton ML, Goeminne PC, Cao B, Humbert M, Shteinberg M, et al. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. *Eur Respir J.* 2021 Apr 15;57(4):2100048.
16. Thirkell P, Griffiths M, Waller MD. Management of Coronavirus Disease 2019 (COVID-19) Pneumonia. *Ref Modul Biomed Sci.* 2021/05/06. 2021;B978-0-08-102723-3.00187-6.
17. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. *N Engl J Med.* 2020;383(19):1827–37.
18. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 — Final Report. *N Engl J Med.* 2020;383(19):1813–26.
19. Pasquini Z, Montalti R, Temperoni C, Canovari B, Mancini M, Tempesta M, et al. Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU. *J Antimicrob Chemother.* 2020 Nov 1;75(11):3359–65.
20. Halaji M, Heiat M, Faraji N, Ranjbar R. Epidemiology of COVID-19: An updated review. *J Res Med Sci.* 2021 Sep 30;26:82.
21. Bulut C, Kato Y. Epidemiology of COVID-19. *Turkish J Med Sci.* 2020 Apr 21;50(SI-1):563–70.
22. Kementrian Kesehatan RI. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (Covid-19) Revisi ke-5. Kementrian Kesehatan RI. 2020.
23. Ali MJ, Hanif M, Haider MA, Ahmed MU, Sundas F, Hirani A, et al. Treatment Options for COVID-19: A Review. *Front Med.* 2020 Jul 31;7:480.
24. Frediansyah A, Nainu F, Dhama K, Mudatsir M, Harapan H. Remdesivir and its antiviral activity against COVID-19: A systematic review. *Clin Epidemiol Glob Heal.* 2020/08/07. 2021;9:123–7.
25. Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et al. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. *ACS Cent Sci.* 2020/05/04. 2020 May 27;6(5):672–83.
26. Singh AK, Singh A, Singh R, Misra A. Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. *Diabetes Metab Syndr.* 2020/05/12. 2020;14(4):641–8.
27. Neldi V, Suharjono S. Remdesivir: Mechanism and Effectiveness for Coronavirus Disease 2019 (COVID-19). *Pharm Sci Res.* 2020;7(4):39–48.
28. Mechineni A, Kassab H, Manickam R. Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical

- effectiveness. *Expert Opin Drug Saf.* 2021 Nov;20(11):1299–307.
- 29. Aleem A, Kothadia Jiten P. Remdesivir. In: StatPearls [Internet] [Internet]. 2021 [cited 2021 Dec 9]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK563261/>
 - 30. Nile SH, Nile A, Qiu J, Li L, Jia X, Kai G. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. *Cytokine Growth Factor Rev.* 2020;53:66–70.
 - 31. Garibaldi BT, Wang K, Robinson ML, Zeger SL, Bandeen-Roche K, Wang MC, et al. Comparison of Time to Clinical Improvement with vs without Remdesivir Treatment in Hospitalized Patients with COVID-19. *JAMA Netw Open.* 2021;4(3):1–14.
 - 32. Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. *N Engl J Med.* 2022;386(4):305–15.
 - 33. Perrotta F, Corbi G, Mazzeo G, Boccia M, Aronne L, D’Agnano V, et al. COVID-19 and the elderly: insights into pathogenesis and clinical decision-making. *Aging Clin Exp Res.* 2020/06/16. 2020 Aug;32(8):1599–608.
 - 34. Kanai O, Fujita K, Nanba K, Esaka N, Hata H, Seta K, et al. Safety of Remdesivir for Patients 80 Years of Age or Older with Coronavirus Disease 2019 (COVID-19). *Drugs Aging.* 2021/12/02. 2021 Dec;38(12):1067–74.
 - 35. Ahmed SB, Dumanski SM. Sex, gender and COVID-19: a call to action. *Can J Public Health.* 2020/09/29. 2020 Dec;111(6):980–3.
 - 36. Lee S, Santarelli A, Caine K, Schritter S, Dietrich T, Ashurst J. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital’s Experience. *J Am Osteopath Assoc.* 2020 Dec;120(12):926–33.
 - 37. Shanbhag V, Arjun NR, Chaudhuri S, Pandey AK. Utility of age-adjusted charlson comorbidity index as a predictor of need for invasive mechanical ventilation, length of hospital stay, and survival in covid-19 patients. *Indian J Crit Care Med.* 2021;25(9):987–91.
 - 38. Jeck J, Jakobs F, Kron A, Cornely OA, Kron F. Retrospective modelling of hospital bed capacities associated with the administration of remdesivir during the first wave of COVID-19 in a German metropolitan city. *J Antimicrob Chemother.* 2022;77(3):753–7.
 - 39. Joo EJ, Ko JH, Kim SE, Kang SJ, Baek JH, Heo EY, et al. Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study. *J Korean Med Sci.* 2021;36(11):1–13.
 - 40. Antinori S, Cossu MV, Ridolfo AL, Rech R, Bonazzetti C, Pagani G, et al. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and

- differences in post-treatment hospitalisation status. *Pharmacol Res.* 2020;158:104899.
41. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. *N Engl J Med.* 2020;382(24):2327–36.
 42. Lee S, Santarelli A, Caine K, Schritter S, Dietrich T, Ashurst J. Remdesivir for the treatment of severe covid-19: A community hospital's experience. *J Am Osteopath Assoc.* 2020;120(12):926–33.
 43. Simioli F, Nicoletta C, Valentino MR, Martino M, Annunziata A, Carannante N, et al. Remdesivir in severe covid-19 and non-invasive ventilation: A real-life experience. *Healthc.* 2021;9(9):1–9.
 44. Mehta RM, Bansal S, Bysani S, Kalpakam H. A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis. *Int J Infect Dis.* 2021;106:71–7.
 45. Gupte V, Hegde R, Sawant S, Kalathingal K, Jadhav S, Malabade R, et al. Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database. *BMC Infect Dis.* 2022;22(1):1–8.
 46. Elshaboury RH, Monk MM, Bebell LM, Bidell MR, Adamsick ML, Gandhi RG, et al. Remdesivir use and outcomes during the FDA COVID-19 emergency use authorization period. *Ther Adv Infect Dis.* 2021;8:1–11.
 47. Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial. *JAMA - J Am Med Assoc.* 2020;324(11):1048–57.
 48. Abd-Elsalam S, Salama M, Soliman S, Naguib AM, Ibrahim IS, Torky M, et al. Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial. *Am J Trop Med Hyg.* 2022;106(3):886–90.
 49. Butt B, Hussain T, Jarrar M, Khalid K, Albaker W, Ambreen A, et al. Efficacy and Safety of Remdesivir in COVID-19 Positive Dialysis Patients. *Antibiotics.* 2022;11(2):1–12.
 50. Jun T, Nirenberg S, Weinberger T, Sharma N, Pujadas E, Cordon-Cardo C, et al. Analysis of sex-specific risk factors and clinical outcomes in COVID-19. *Commun Med.* 2021;1(1).
 51. Acharya TA, Joshi KJ, Patel DD, Shah SN, Mehta DS. Study of Clinical Outcome and Healthcare Modalities of COVID-19 Patients Treated With Remdesivir at a Tertiary Care Teaching Hospital. *Cureus.* 2022;14(1):1–8.
 52. Qureshi QH, Ashraf T, Rehman K, Khosa MK, Akash MSH. Therapeutic interventions of remdesivir in diabetic and nondiabetic COVID-19 patients:

- A prospective observational study conducted on Pakistani population. *J Med Virol.* 2021;93(12):6732–6.
- 53. Madan S, Patel A, Sharan K, Ghosh S, Venugopal V, Shah N, et al. Remdesivir for the treatment of COVID-19 disease: A retrospective comparative study of patients treated with and without Remdesivir. *medRxiv.* 2021;1(165):1–13.
 - 54. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. *Diabetes Metab Syndr Clin Res Rev.* 2020;14(4):303–10.
 - 55. Jeck J, Jakobs F, Kron A, Franz J, Cornely OA, Kron F. A cost of illness study of COVID-19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic “first wave” in a German tertiary care hospital. *Infection.* 2022;50(1):191–201.
 - 56. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet.* 2020;395(10236):1569–78.

